Alzheimer's Disease: Issues and Challenges in Primary Care

https://doi.org/10.1016/j.cnur.2005.09.005Get rights and content

Section snippets

The Clinical Dilemma in Primary Care

Approximately 4.5 million Americans are affected by Alzheimer's disease (AD), and the prevalence is predicted to increase to 13.2 million by 2050 [1]. Advancing age is the single greatest risk factor to develop AD. The number of newly diagnosed individuals with AD, as shown in Fig. 1, increases from about 0.17% at 65 years of age to 3% at 85 years of age, with a dramatic increase to 8% per year after age 85 [2]. These United States prevalence and incidence figures are consistent with similar

Screening in Primary Care Practice

In a traditional model of secondary preventive services, detection of early stage disease and treatment efficacy is fundamental in determining the clinical value of a screening test. It fails to take into account the burden of mistaking the earliest symptoms for another condition or not knowing the diagnosis to adequately plan for the future. Apparent cognitive or functional decline always is relevant clinically, regardless of how mild the symptoms may be. Informing patients and their family

Brief Cognitive Tests

The Mini-Mental State Exam (MMSE) tests memory, orientation, and attention, as well as ability to name, follow verbal and written instructions, write a sentence, and copy an intersecting polygon [5]. A score of 24 or above, out of a maximum score of 30 is considered normal, though age and education influences the result. Generally, increased age and lower education level attainment result in lower MMSE scores. In a large-scale population study, the median MMSE score in a 75-year-old person

Functional and Behavioral Assessment

Functional and behavioral symptoms are not correlated necessarily with cognitive symptoms in AD; therefore, detailed functional and behavioral assessments should be included as part of an initial or serial cognitive assessment. Functional impairment in advanced activities of daily living (AADLs), such as work, hobbies, or social activities and instrumental activities of daily living (IADLs), such as shopping, household maintenance, money management, driving, cooking, laundry, and use of the

Staging AD

Disease severity is categorized commonly into mild, moderate, and severe stages. Mild stage AD is the longest, typically occurring up to 4 years, moderate stage occurring 2 to 3 years, and severe stage occurring 1 to 3 years. It is clinically useful to characterize severe stage disease further into profound and terminal stages to help predict the time when hospice services will benefit the patient and family.

Stage-defined characteristics include cognition, behavior, and functional abilities, as

Family Caregivers

Most people who have AD are cared for at home by family or friends spending an average of 17.6 hours per week giving care [12]. The caregiver, often a daughter or daughter-in-law, has a critical role in maintaining the patient's overall quality of life and is at risk themselves for psychiatric and physical morbidity from the stresses of caregiving [10]. Several studies report improved patient and caregiver outcomes with interventions directed at the caregiver. A randomized controlled trial of

Pharmacologic Interventions

At each stage of AD, nurses should consider the clinical benefits and adverse effects of pharmacologic interventions in the care of the patient. Because patients rely on a caregiver to administer medications and monitor response, nurses need to develop good communication patterns with the caregiver and have useful educational materials on hand to distribute at a primary care visit or to recommend for outside readings and resources. Web-based literature and sites, such as the Alzheimer's

Summary

As the number of individuals who have AD continues to increase, nurses become the frontline providers in primary care settings. The challenge is to recognize early symptoms and intervene by preparing the person who has AD and caregivers through the progression of the disease. By counseling, educating, and supporting the caregiver and maximizing the patient's quality of life through pharmacologic and behavioral interventions, nurses can provide a much-needed broad-based approach to their care.

First page preview

First page preview
Click to open first page preview

References (23)

  • M.F. Folstein et al.

    Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician

    J Psychiat Res

    (1975)
  • G. Grossberg et al.

    Rivastigmine in Alzheimer's disease: efficacy over two years

    Am J Geriatr Psychiatry

    (2004)
  • L.E. Hebert et al.

    Alzheimer disease in the US population: prevalence estimates using the 2000 census

    Arch Neurol

    (2003)
  • R. Brookmeyer et al.

    Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset

    Am J Public Health

    (1998)
  • V.T. Cotter et al.

    Cognitive function assessment in individuals at risk for Alzheimer's disease

    JAANP

    (2003)
  • M.C. Tierney et al.

    Contribution of informant and patient ratings to the accuracy of the Mini-Mental State Examination in predicting probable Alzheimer's disease

    JAGS

    (2003)
  • R.M. Crum et al.

    Population-based norms for the Mini-Mental State Examination by age and educational level

    JAMA

    (1993)
  • S. Borson et al.

    The Mini-Cog as a screen for dementia: validation in a population-based sample

    JAGS

    (2003)
  • C.M. Clark et al.

    Performance of the Dementia Severity Rating Scale: a caregiver questionnaire for rating severity in Alzheimer disease

    Alzheimer Dis Assoc Disord

    (1996)
  • M. Steinberg et al.

    The incidence of mental and behavioral disturbances in dementia: the CACHE County study

    J Neuropsychiatry Clin Neurosci

    (2003)
  • R. Schulz et al.

    Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes

    Gerontologist

    (1995)
  • Cited by (18)

    • Using artificial neural networks to select the parameters for the prognostic of mild cognitive impairment and dementia in elderly individuals

      2017, Computer Methods and Programs in Biomedicine
      Citation Excerpt :

      Even further, there is a more secure proof that the available drugs can prevent an eventual progression of the disease. There are indications that it may lead to a stabilization of the disease, delay in cognitive and functional impairment, to provide a better quality of life for the patient and his family [41]. Another point to observe is related to the physicians should advise patients and their families regarding the results that may arise during treatment with these agents, with mild to moderate adverse effects (nausea, vomiting, diarrhea or others) [42].

    View all citing articles on Scopus
    View full text